XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Collaboration And Other Agreements [Line Items]            
Revenues   $ 20,257,000 $ 10,593,000 $ 33,939,000 $ 20,255,000  
Deferred revenue, current   9,267,000   9,267,000   $ 10,700,000
Zai Lab Agreement | Zai Labs            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment $ 25,000,000.0          
Non-refundable upfront payment, net of tax withholding 22,500,000          
Nonrefundable payment tax withholding $ 2,500,000          
Potential development and regulatory milestone payments under agreement   140,000,000.0   140,000,000.0    
Revenues       4,000,000.0    
Revenues, Net Of Tax Withholding   0 4,000,000.0 3,600,000 8,100,000  
Revenues, Tax Withholding       400,000    
Deferred revenue, current   5,000,000.0   5,000,000.0   $ 5,000,000.0
Zai Lab Clinical Supply Agreements | Zai Labs            
Collaboration And Other Agreements [Line Items]            
Revenues   $ 300,000 $ 0 $ 1,300,000 $ 0  
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum            
Collaboration And Other Agreements [Line Items]            
Potential proceeds from royalties (percent) 20.00%          
Zai Lab Agreement, TRIDENT molecule | Zai Labs            
Collaboration And Other Agreements [Line Items]            
Potential proceeds from royalties (percent) 10.00%